<!doctype html>
<html class="no-js" lang="en">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=0, minimum-scale=1.0, maximum-scale=1.0">
    <meta name="format-detection" content="telephone=no">
    <title>References</title>
    <link rel="stylesheet" href="../shared/css/global.css" type="text/css">
    <link rel="stylesheet" href="../shared/css/icons.css" type="text/css">
    <link rel="stylesheet" href="css/slide.css" type="text/css">
    <script type="text/javascript" src="../shared/js/vendor/modernizr.js"></script>
  </head>
  <body id="A105" data-group="A100" data-trace="trace_a105.jpg">
		<nav data-topnav></nav>
  	<div class="row">
	    <main class="columns">
	      <h1>References</h1>
	      <p><b class="grape">1.</b>&nbsp;KENGREAL<sup>&reg;</sup> (cangrelor) Prescribing Information. 2016. <b class="grape">2.</b>&nbsp;Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y<sub>12</sub> receptor antagonist. <em>J Clin Pharmacol.</em> 2010;50(1):27-35. <b class="grape">3.</b>&nbsp;Data on file. Chiesi USA, Inc. <b class="grape">4.</b>&nbsp;Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. <em>N Engl J Med.</em> 2013;368(14):1303-1313. <b class="grape">5.</b>&nbsp;Stone GW, Genereux P, White HD, et al. TCT-79 efficacy of cangrelor in lesions with high-risk and low-risk angiographic characteristics: the CHAMPION PHOENIX trial. <em>J Am Coll Cardiol.</em> 2015;66(15):B36-B37. <b class="grape">6.</b>&nbsp;Thel M, Califf RM, Tardiff BE, et al. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II): Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. <em>Am J Cardiol.</em> 2000;85(4):427-434. <b class="grape">7.</b>&nbsp;Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <em>Eur Heart J.</em> 2016;37(3):267-315. <b class="grape">8.</b>&nbsp;Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <em> J Am Coll Cardiol.</em> 2011;58:e44-e122. <b class="grape">9.</b>&nbsp;Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. <em>N Engl J Med.</em> 2006;355(21):2203-2216.</p>
        <p>KENGREAL<sup>&reg;</sup> is a registered trademark of Chiesi Farmaceutici S.p.A. <br>&copy;2017 Chiesi USA, Inc. All rights reserved. Created in the USA. 12/16 PP-K-0096 V1.0</p>
	    </main>
	    <aside class="columns" data-sidebar>
	    	<figure data-logo class="logo text-center"></figure>
	    	<div data-isi class="hide"></div>
	    </aside>
	  </div>
	  <section class="row" data-footer></section>
    <div id="modals"></div>
    <script type="text/javascript" src="../shared/js/vendor/jquery.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/veeva-library-4.2.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/ivaHelper-1.0.1.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/jquery.touchSwipe.min.js"></script>
    <script type="text/javascript" src="../shared/js/vendor/iscroll.js"></script>
    <script type="text/javascript" src="../shared/js/global.js"></script>
    <script type="text/javascript" src="js/slide.js"></script>
  </body>
</html>